Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10922725 | 1.00 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL11160476 | 1.00 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL11160502 | 1.00 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL11169755 | 1.00 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL11164590 | 1.00 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL3855592 | 0.98 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL5645169 | 0.93 | CNR1 (0.51) | CNR2CNR1 | |
| SCHEMBL5648833 | 0.86 | CNR1 (0.43) | CNR2CNR1 | |
| SCHEMBL10639109 | 0.83 | CNR1 (0.43) | CNR2CNR1 | |
| SCHEMBL4887812 | 0.83 | CNR1 (0.77) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-119585361-A | E/E assembly containing polycarbonate material with high tracking resistance | 科思创德国股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-114007603-A | Compositions and methods for neuroprotection using cannabinoids | 因美制药公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD (IL) | 2021-01-14 | — | — | US | disclosed |
| WO-2019159168-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD. (IL) | 2019-08-22 | — | — | WO | disclosed |
| WO-2017180528-A1 | METHODS OF TREATMENT WITH SELECTIVE CB2 RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| CN-101119951-A | Conditioning agents | UCL BIOMEDICA PLC (GB) | 2008-02-06 | — | — | CN | disclosed |
| WO-2006067450-A2 | MODULATOR | UCL BIOMEDICA PLC (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2004078261-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-09-16 | — | — | WO | disclosed |
| US-4391827-A | 3-(2-Hydroxy-4-(substituted)phenyl)-cycloalkanone and cycloalkanol analgesic agents and intermediates therefor | PFIZER INC. (US) | 1983-07-05 | — | — | US | disclosed |
| US-4387229-A | ANALGESICS, TRANQUILIZERS, SEDATIVES | PFIZER INC. (US) | 1983-06-07 | — | — | US | disclosed |
| US-4332942-A | 3-(2-Hydroxy-4-(substituted)phenyl)azacycloalkanes as analgesics | PFIZER, INC. (US) | 1982-06-01 | — | — | US | disclosed |
| US-4306097-A | 3-[2-Hydroxy-4-(substituted)phenyl]-cycloalkanol analgesic agents | PFIZER INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4284829-A | Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives | PFIZER INC. (US) | 1981-08-18 | — | — | US | disclosed |
| US-4283569-A | Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives | PFIZER INC. (US) | 1981-08-11 | — | — | US | disclosed |
| US-4263438-A | 3-[2,4-(Disubstituted)-phenyl]azacycloalkanones as analgesics | PFIZER INC. (US) | 1981-04-21 | — | — | US | disclosed |
| US-4147872-A | 3-[2-Hydroxy-4-(substituted)-phenyl]azacycloalkanes and derivatives thereof as analgesic agents and intermediates therefor | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | CNR1, GLRA1, GLRA3 | CNR2 4/4885CNR1 1/4885 |
| US-20080262011-A1 | Modulator | CHRNA10, CNR1, CHRNA9 | CNR2 12/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.